Credit Suisse Group initiated coverage on shares of Checkmate Pharmaceuticals (NASDAQ:INBX) in a research report sent to investors on Monday, Benzinga reports. The firm issued an outperform rating and a $26.00 target price on the stock.
INBX stock opened at $17.30 on Monday. Checkmate Pharmaceuticals has a 1-year low of $15.76 and a 1-year high of $26.98.
In other news, major shareholder Global Investors Lp Viking purchased 180,219 shares of the stock in a transaction dated Wednesday, August 26th. The stock was acquired at an average price of $18.92 per share, for a total transaction of $3,409,743.48. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Checkmate Pharmaceuticals Company Profile
Inhibrx, Inc, a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors.
Featured Article: Moving Average Convergence Divergence (MACD)
Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.